Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d0d51806567d8f1e090d1507c5f6dd3a |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4816 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1617 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1611 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
filingDate |
2014-02-06^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2015-02-03^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e1b2b12c8f95c91fd2a9ce7502ef0ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e098fc599f7fa2242cc1ff3d18498756 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efd8b588b80c60aa631c09bf5270e844 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03c5f3c5f8dc1a6903db44eade6e388d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb25fd371d36152fa9c872c4938c0d41 |
publicationDate |
2015-02-03^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-8945612-B2 |
titleOfInvention |
Capsules containing high doses of levodopa for pulmonary use |
abstract |
The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9539211-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9642812-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10238607-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015342890-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018036253-A1 |
priorityDate |
2012-11-09^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |